Progress of CD200 in hematological malignancies
10.3760/cma.j.cn115356-20190916-00179
- VernacularTitle:CD200在血液系统肿瘤中的研究进展
- Author:
Ting XIA
1
;
Jinjun HU
;
Zhifang XU
Author Information
1. 山西医科大学第二临床医学院 山西医科大学第二医院血液病研究所 血液病分子诊疗山西省重点实验室，太原 030001
- From:
Journal of Leukemia & Lymphoma
2020;29(7):445-448
- CountryChina
- Language:Chinese
-
Abstract:
The antigen of cluster of differentiation CD200 is widely expressed in hematological malignancies, and is of great significance for the diagnosis, monitoring of minimal residual disease and prognosis evaluation of B cell lymphoproliferative disorders, multiple myeloma and acute leukemia. In addition, CD200 plays an important regulatory role in tumor immune tolerance, suggesting that CD200 is a potential molecular target for the immunotherapy of hematological malignancies.
